Table 4.
Sample | F+ | P+ | O+ | C+ | F− | P− | O− | C− |
---|---|---|---|---|---|---|---|---|
Cumulative IB conjugates excreted in 24 h urine [μmol ± SD] | 0.15 ± 0.02ac | 0.16 ± 0.05ab | 0.21 ± 0.08ac | 0.23 ± 0.06c | 0.15 ± 0.07 | 0.14 ± 0.07 | 0.11 ± 0.03 | 0.12 ± 0.08 |
IB bioavailability (%) calculated as cumulative IB/GI μmol in before incorporation in the gels | n.a. | n.a. | n.a. | n.a. | 11.8 ± 5.2 | 10.5 ± 5.3 | 8.6 ± 2.6 | 9.2 ± 5.8 |
IB bioavailability (%) calculated as cumulative IB/IB μmol in before incorporation in the gels | 27.2 ± 3.9 | 28.6 ± 8.3 | 38.2 ± 14.0 | 41.1 ± 11.6 | n.a. | n.a. | n.a. | n.a. |
Peak time (t max, h ± SD) for IB conjugate excretion | 1.48 ± 0.51 | 2.28 ± 1.43 | 1.82 ± 0.46 | 1.94 ± 0.52 | 8.06 ± 2.12 | 9.52 ± 3.51 | 9.26 ± 3.69 | 8.07 ± 2.75 |
n.a., not applicable.
Different letters within each row of the cumulative IB conjugates values for the samples (for each set of sample (−) and (+)) indicate significant differences (p < 0.05). The absence of letters indicates no significant difference.